Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA ...
Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )
6 Jun 2022
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper resp...
Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )
6 Jun 2022
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer P...
Dr Pamela Kunz - Yale Cancer Center, New Haven, USA
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )
6 Jun 2022
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...
Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
6 Jun 2022
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )
6 Jun 2022
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )
5 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significanc...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )
5 Jun 2022
(RVd) ± , stem cell transplantation and R maintenance shows significance for new...
Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA
(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022